SAN FRANCISCO and GENEVA, July 14, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced positive analytical performance data for the Company's proprietary cell cycle dysregulation diagnostic blood assay LymPro Test®, currently under development for Alzheimer's disease diagnosis. The analytical data package, produced at the Company's contract laboratory BD Biosciences, provides the basis for reproducible clinical performance assessment of LymPro Test®. The Company has performance univariate and multivariate analytical data analyses in an Alzheimer's population vs. a non-Alzheimer's population (cognitively intact, Parkinson's dementia and vascular dementia) to assess clinical performance. The Company will present pilot clinical performance data, and an up-to 6 year longitudinal assessment of the patients' clinical diagnosis change over time, in two complementary poster presentations on Tuesday July 15th, 2014 at 11:45am local at AAIC 2014 in Copenhagen, Denmark (Poster position 117 and 118).
"We are pleased with the reproducibility we have seen with the assay at BD," commented Paul Jorgensen, Head of Diagnostics Product Development at Amarantus. "We evaluated various conditions for assay performance and were able to clearly demonstrate suitable analytical performance that will underpin the validity of the ability of LymPro to differentiate Alzheimer's from non-Alzheimer's using both univariate and multivariate models. We are pleased to be sharing the data, along with a scientific and clinical data summary to support the cell cycle dysregulation hypothesis in Alzheimer's disease."
The contract laboratory evaluated the ability of specific mitogens to upregulate the cell surface marker CD69 in various subpopulations of peripheral blood lymphocytes. The data showed clear and consistent measurements of CD69 on an individual lymphocyte subpopulation basis, and an overall lymphocyte population basis. This confirms previously published work on LymPro (Stieler et al, 2001, and Stieler et al, 2012) and allows Amarantus to generate meaningful univariate measurements and multivariate models that may allow for the differentiation of Alzheimer's patients from non-Alzheimer's patients. A copy of the poster presentation can be found at http://www.amarantus.com/aJCPUuWU.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. AMBS has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready small molecule indicated for Parkinson's Levodopa induced dyskinesia and Adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. AMBS also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). Amarantus operations are located at Janssen Labs @QB3 in San Francisco, CA. For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.
Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements." These forward-looking statements generally are identified by the words believes," project," expects," anticipates," estimates," intends," strategy," plan," may," will," would," will be," will continue," will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.
CONTACT: Amarantus Bioscience Holdings, Inc.: Aimee Boutcher, Investor Relations 408.737.2734 x 101 firstname.lastname@example.org
Source:Amarantus BioScience Holdings, Inc.